EUVIMEDEUVIMED entdecken
Open Access

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer

James T Topham, Chris J O'Callaghan, Harriet Feilotter, Hagen F Kennecke iD, Young S Lee iD, Weimin Li, Kimberly C Banks iD, Katie Quinn, Daniel J Renouf, Derek J Jonker, Dongsheng Tu iD, Eric X Chen iD und 1 weitere

Journal of Clinical Oncology · 20.01.2023 · 41 (3) · 485-496

DOI: 10.1200/jco.22.00364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2023. Verfasst von James T Topham und 12 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colorectal Neoplasms. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Anti–epidermal growth factor receptor (EGFR) antibodies are effective treatments for metastatic colorectal cancer. Improved understanding of acquired resistance mechanisms may facilitate circulating tumor DNA (ctDNA) monitoring, anti-EGFR rechallenge, and combinatorial strategies to delay resistance. METHODS Patients with treatment-refractory metastatic colorectal cancer (n = 169) enrolled on the CO.26 trial had pre–anti-EGFR tissue whole-exome sequencing (WES) compared with baseline and week 8 ctDNA assessments with the GuardantOMNI assay. Acquired alterations were compared between patients with prior anti-EGFR therapy (n = 66) and those without. Anti-EGFR therapy occurred a median of 111 days before ctDNA assessment. RESULTS ctDNA identified 12 genes with increased mutation frequency after anti-EGFR therapy, including EGFR ( P = .0007), KRAS ( P = .0017), LRP1B ( P = .0046), ZNF217 ( P = .0086), MAP2K1 ( P = .018), PIK3CG ( P = .018), BRAF ( P = .048), and NRAS ( P = .048). Acquired mutations appeared as multiple concurrent subclonal alterations, with most showing decay over time. Significant increases in copy-gain frequency were noted in 29 genes after anti-EGFR exposure, with notable alterations including EGFR ( P < .0001), SMO ( P < .0001), BRAF ( P < .0001), MET ( P = .0002), FLT3 ( P = .0002), NOTCH4 ( P = .0006), ERBB2 ( P = .004), and FGFR1 ( P = .006). Copy gains appeared stable without decay 8 weeks later. There were 13 gene fusions noted among 11 patients, all but one of which was associated with prior anti-EGFR therapy. Polyclonal resistance was common with acquisition of ≥ 10 resistance related alterations noted in 21% of patients with previous anti-EGFR therapy compared with 5% in those without ( P = .010). Although tumor mutation burden (TMB) did not differ pretreatment ( P = .63), anti-EGFR exposure increased TMB ( P = .028), whereas lack of anti-EGFR exposure resulted in declining TMB ( P = .014). CONCLUSION Paired tissue and ctDNA sequencing identified multiple novel mutations, copy gains, and fusions associated with anti-EGFR therapy that frequently co-occur as subclonal alterations in the same patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColorectal NeoplasmsHumansAntibodiesBiomarkers, TumorDrug Resistance, NeoplasmMutationProto-Oncogene Proteins B-rafNeoplasm Metastasis

Substanzen

AntibodiesBiomarkers, TumorCirculating Tumor DNAProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • BC Cancer, University of British Columbia, Vancouver, BC, Canada.
  • Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
  • Providence Health, Portland, OR.
  • AstraZeneca, Gaithersburg, MD.
  • Guardant Health, Redwood City, CA.
  • The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.

ORCID-Profile: Hagen F Kennecke, Young S Lee, Kimberly C Banks, Dongsheng Tu, Eric X Chen, Jonathan M Loree

Zitieren

APA

Topham, J. T., O'Callaghan, C. J., Feilotter, H., Kennecke, H. F., Lee, Y. S., Li, W., Banks, K. C., Quinn, K., Renouf, D. J., Jonker, D. J., Tu, D., Chen, E. X., & Loree, J. M. (2023). Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 41(3), 485-496. https://doi.org/10.1200/jco.22.00364

Vancouver

Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Lee YS, Li W, et al. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. Journal of Clinical Oncology. 2023;41(3):485-496. doi:10.1200/jco.22.00364

BibTeX
@article{Topham2023,
  author = {Topham, James T and O'Callaghan, Chris J and Feilotter, Harriet and Kennecke, Hagen F and Lee, Young S and Li, Weimin and Banks, Kimberly C and Quinn, Katie and Renouf, Daniel J and Jonker, Derek J and Tu, Dongsheng and Chen, Eric X and Loree, Jonathan M},
  title = {Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {3},
  pages = {485--496},
  doi = {10.1200/jco.22.00364}
}
Kostenlos starten →